Multiple myeloma
Conditions
Interventions
The nasal spray group (N gruop):Butorphanol tartrate nasal spray, 1 spray each time (equivalent to 1 mg)
Sponsors
Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-70 years old; 2. Patients with multiple myeloma; 3. VAS score 3 to 6 points; 4. Patients with normal liver and kidney function; 5. Patients with normal ECG; 6. Patients without chemotherapy during medication; 7. Patients without PCIA.
Exclusion criteria
Exclusion criteria: 1. Patients known to be allergic to butorphanol or other research drugs; 2. Patients with long-term use of narcotic analgesics or non steroidal anti-inflammatory drugs; 3. Opioid dependent or opioid tolerant patients; 4. Patients with serious diseases of nasal mucosa; 5. Severe cardiac / circulatory dysfunction (systolic blood pressure >=180 mmHg and / or diastolic blood pressure >= 110 mmHg; systolic blood pressure 24 times / min), kidney (creatinine clearance rate <=30 ml/min); 6. Patients with mental disorders or other reasons that are difficult to cooperate with; 7. Patients taking stimulant CNS drugs or suffering from CNS disease or respiratory dysfunction at the same time; 8. Patients with a history of mental illness; 9. Patients who participated in other drug clinical studies in recent three months; 10. Subjects considered unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ramsay;bruggrmann comfort scale; | — |
Countries
China
Contacts
Public ContactLi Xiaoming
Department of Hematology, Affiliated Hospital of Southwest Medical University
Outcome results
None listed